Torisel (temsirolimus)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Wyeth |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell carcinoma, is being studied for treatment of multiple myeloma in combination with Velcade (bortezomib) and dexamethasone (Decadron). Torisel inhibits the mammalian target of rapamycin (mTOR), which is a critical protein for cancer cell growth.
Clinical Trials:
For a list of clinical trials studying Torisel for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for Torisel: http://www.torisel.com/
Related Articles:
- Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
- Torisel And Velcade Combination Shows Promise As Treatment For Relapsed/Refractory Multiple Myeloma (ASH 2010)
- Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
- New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
- Anti-Cancer Drug Zolinza Shows Potential In Myeloma
Leave a comment